Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-16

Clinical Trial Update: Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL) [Phase 2]

View source ↗

Summary

Phase 2 study of AKCEA-ANGPTL3-LRx (ISIS 703802) in familial partial lipodystrophy has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AKCEA-ANGPTL3-LRx (AKCEA-ANGPTL3-LRx)

Snippet

Sponsor: Akcea Therapeutics | Conditions: Familial Partial Lipodystrophy | Phase 2 | Status: COMPLETED | Results posted: 2021-02-16